JP5553337B2 - Marine fish white spot disease preventive and therapeutic agent - Google Patents

Marine fish white spot disease preventive and therapeutic agent Download PDF

Info

Publication number
JP5553337B2
JP5553337B2 JP2010016279A JP2010016279A JP5553337B2 JP 5553337 B2 JP5553337 B2 JP 5553337B2 JP 2010016279 A JP2010016279 A JP 2010016279A JP 2010016279 A JP2010016279 A JP 2010016279A JP 5553337 B2 JP5553337 B2 JP 5553337B2
Authority
JP
Japan
Prior art keywords
fish
white spot
spot disease
marine fish
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010016279A
Other languages
Japanese (ja)
Other versions
JP2011153103A (en
Inventor
知義 良永
早予子 西田
賢貞 林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Priority to JP2010016279A priority Critical patent/JP5553337B2/en
Publication of JP2011153103A publication Critical patent/JP2011153103A/en
Application granted granted Critical
Publication of JP5553337B2 publication Critical patent/JP5553337B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81Aquaculture, e.g. of fish

Landscapes

  • Feed For Specific Animals (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

本発明は、海産魚に寄生するCryptocaryon irritansによる白点病の予防治療剤に関する。   The present invention relates to a prophylactic / therapeutic agent for white spot disease caused by Cryptocaryon irritans parasitic on marine fish.

ヒラメやタイ等の海産魚の感染症の一つに白点病がある。養殖場で白点病が発生すると、大量死が発生し、その被害は甚大である。   White spot disease is one of the infectious diseases of marine fish such as flounder and Thailand. When white spot disease occurs in the farm, mass death occurs and the damage is enormous.

海産魚白点病の原因は、淡水魚白点病の原因寄生虫と同じく繊毛虫ではあるものの、全く異なる分類群に属するCryptocaryon irritansという寄生虫である。Cryptocaryon irritansの生活史は以下のようなものである。すなわち、水中に漂っているセロント(感染幼虫)が魚体の体表、鰭、鰓に接触すると、これらの鰓や体表の上皮の細胞層の中に侵入し、トロホント(感染期虫体)として成長する。成長したトロホントは魚体から離脱し、プロトモントとなり、水底に沈む。水底に沈んで数時間たつと、シスト化したトモント(シスト期虫体)となる。このトモントの中で細胞分裂を繰り返して仔虫が形成され、セロントとして水中に放出される。魚体内で成長して離脱するまでの日数、シストからセロントが放出されるまでの日数は、温度に左右されるが、水温25度では、それぞれ、3から4日ならびに4から10日間ほどである。   Although the cause of marine fish white spot disease is a ciliate as well as the causative parasite of freshwater fish white spot disease, it is a parasite called Cryptocaryon irritans belonging to a completely different taxon. The life history of Cryptocaryron irritans is as follows. That is, when the seron (infected larva) drifting in the water touches the body surface, wings, and wings of the fish body, it enters the cell layer of the epithelium of these wings and body surface, and becomes a trohont (infectious worm body) grow up. Grown trophon leaves the fish, becomes a protomont and sinks to the bottom of the water. When it sinks to the bottom of the water for several hours, it becomes a cystized tomont. In this tomont, larvae are formed by repeating cell division and released into the water as a seront. The number of days until the fish grows and leaves, and the number of days until the seront is released from the cyst depends on the temperature, but at a water temperature of 25 degrees, it is about 3 to 4 days and 4 to 10 days, respectively. .

白点病の特徴は、魚体に虫体が侵入しただけで魚が死亡するのではなく、魚体内で虫体が成長する際および魚体から虫体が離れる際に魚体を傷害すること、及びその傷害に基づいて死亡することである。   The characteristic of white spot disease is that the fish body is not killed when the insect body invades into the fish body, but the fish body is damaged when the insect body grows and leaves the fish body. To die based on injury.

白点病の原因であるCryptocaryon irritansは、多くの魚類寄生虫と同様、試験管内で成長させることができないため、その予防治療剤の開発は極めて困難である。   Since Cryptocarriton irritans, which is the cause of white spot disease, cannot be grown in vitro like many fish parasites, the development of preventive and therapeutic agents is extremely difficult.

海産魚白点病予防治療剤としては、塩化リゾチーム、ラクトフェリン、中鎖脂肪酸などが知られている(非特許文献1、2、3)が、前者二つは虫体に直接作用するのではなく、その効果は魚類の粘液分泌促進や生体防御能の向上によるものと考えられている。また、中鎖脂肪酸は、魚体侵入前の虫体に対する殺虫効果は知られているが、魚体内の虫体への作用機序は不明である。   As anti-fish white spot disease preventive and therapeutic agents, lysozyme chloride, lactoferrin, medium chain fatty acids and the like are known (Non-Patent Documents 1, 2, and 3), but the former two do not act directly on the worm body. The effect is thought to be due to the promotion of mucus secretion in fish and the improvement of biological defense ability. In addition, medium chain fatty acids are known to have an insecticidal effect on worms before entering the fish body, but the mechanism of action on worms in the fish body is unknown.

白点病に対する対策としては、水槽などの閉鎖的な環境にある鑑賞魚用としては、飼育水へ銅イオン、メチレンブルー、マラカイトグリーンなどを長期間添加することにより魚体外の発育段階の虫体を殺すという手法が用いられている。網いけすなどの開放的な環境に飼育されている魚類ではこれらの飼育水への薬剤の添加という手法を採ることはできない。また、これらの薬剤は、食品衛生上の問題から食用魚には使用できない。食用魚に対しては、潮流の早い海域への生簀の移動、塩化リゾチームの薬剤としての投与あるいは中鎖脂肪酸(カプリック酸)の添加物として餌料への投与が行われているが、その効果は限定的で、さらに有効な予防治療法が求められている。   As a countermeasure against white spot disease, for appreciation fish in a closed environment such as an aquarium, add copper ions, methylene blue, malachite green, etc. to the breeding water for a long period of time, so that insects in the developmental stage outside the fish body can be removed. The technique of killing is used. Fish that are raised in an open environment, such as netting, cannot use the method of adding chemicals to these breeding waters. In addition, these drugs cannot be used for food fish due to food hygiene problems. For edible fish, the movement of ginger to the sea area where the tidal current is fast, the administration of lysozyme chloride as a drug or the addition of medium chain fatty acid (capric acid) to the feed, the effect is There is a need for limited and more effective prophylactic treatments.

Fish Pathology,30,4,289−290Fish Pathology, 30, 4, 289-290 Fish & Shellfish Immunology,18,2,109,124Fish & Shellfish Immunology, 18, 2, 109, 124 Aquaculture,198,3−4,219−228Aquaculture, 198, 3-4, 219-228 Disease of Aquatic Organisms,78,2,155−160Disease of Aquatic Organisms, 78, 2, 155-160

本発明の課題は、海産魚の魚体に寄生しているCryptocaryon irritansの虫体に対する殺虫効果を示す白点病予防治療剤を提供することにある。   An object of the present invention is to provide an agent for preventing and treating white spot disease, which exhibits an insecticidal effect on Cryptoccharyon irritans parasites that are parasitic on marine fish.

そこで本発明者は、Cryptocaryon irritans虫体の試験管内培養手段について検討し、魚類の培養細胞層の上に細胞培養用の培地で作られたアガロースゲルを重層して培地とし、細胞層とアガロースゲル層の間にセロントを挿入する方法を採用することにより、この虫体の発育に成功した(非特許文献4)。そして、この系を用いて種々検討したところ、イオノフォア抗生物質が虫体に対する殺虫効果を示し、その効果が魚に寄生している虫体に対して殺虫効果と成長抑制効果を有することを見出した。さらに、海産魚を用いて実際にCryptocaryon irritansの感染実験を行った結果、イオノフォア抗生物質が、白点病による死亡を有意に抑制することを確認し、本発明を完成するに至った。   Therefore, the present inventor examined the in-vitro culture means of Cryptocarriton irritans parasites, and layered agarose gel made of cell culture medium on a cultured cell layer of fish to form a culture medium. The cell layer and agarose gel By adopting a method of inserting a seronto between layers, this parasite was successfully developed (Non-patent Document 4). As a result of various studies using this system, it was found that ionophore antibiotics have an insecticidal effect on worms, and that the effect has an insecticidal effect and a growth inhibitory effect on worms parasitic on fish. . Furthermore, as a result of actually carrying out a Cryptocarriton irritans infection experiment using marine fish, it was confirmed that ionophore antibiotics significantly suppressed death due to white spot disease, and the present invention was completed.

すなわち、本発明は、イオノフォア抗生物質を有効成分とする海産魚白点病予防治療剤を提供するものである。
また、本発明は、イオノフォア抗生物質を海産魚に投与することを特徴とする海産魚白点病の予防治療方法を提供するものである。
That is, the present invention provides a marine fish white spot disease preventive and therapeutic agent comprising an ionophore antibiotic as an active ingredient.
In addition, the present invention provides a method for preventing and treating marine fish white spot disease, which comprises administering an ionophore antibiotic to marine fish.

本発明によれば、海産魚の魚体に寄生しているCryptocaryon irritans虫体に対する殺虫効果と成長抑制効果を有し、海産魚の白点病による死亡数を顕著に抑制することができる。   ADVANTAGE OF THE INVENTION According to this invention, it has the insecticidal effect and growth inhibitory effect with respect to the Cryptocaryon irritans parasite which is parasitic on the fish body of marine fish, and can suppress the death number by the white spot disease of marine fish remarkably.

C.irritansのトロホントの生残率に対するサリノマイシンナトリウムの効果を示す。C. Figure 3 shows the effect of sodium salinomycin on the survival rate of irritans trohont. C.irritansのトロホントの生残率に対するモネンシンナトリウムの効果を示す。C. Figure 6 shows the effect of monensin sodium on the survival rate of irritans trohont. C.irritansのトロホントの生残率に対するナラシンの効果を示す。C. The effect of narasin on the survival rate of irritans trohont is shown. C.irritansのトロホントの生残率に対するセンデュラマイシンナトリウムの効果を示す。C. Figure 2 shows the effect of Senduramycin sodium on the survival rate of irritans trohont. サリノマイシンナトリウムの経口投与(餌料中濃度200ppm)により白点病に対する生残率を示す。The survival rate for white spot disease is shown by oral administration of salinomycin sodium (concentration in feed: 200 ppm).

本発明の海産魚予防治療剤の有効成分は、イオノフォア抗生物質である。該イオノフォア抗生物質としては、サリノマイシン、モネンシン、ナラシン、センデュラマイシン、ラサロシド、それらの塩等が挙げられるが、安全性及び有効性の点からサリノマイシン、モネンシン、ナラシン、センデュラマイシン及びそれらの塩がより好ましく、サリノマイシン又はその塩が特に好ましい。ここで、塩としては、ナトリウム、カリウム等のアルカリ金属塩が好ましい。   The active ingredient of the agent for preventing and treating marine fish of the present invention is an ionophore antibiotic. Examples of the ionophore antibiotics include salinomycin, monensin, nalasin, senduramycin, rasaloside, salts thereof, and the like. More preferred is salinomycin or a salt thereof. Here, as a salt, alkali metal salts, such as sodium and potassium, are preferable.

後記実施例に示すように、イオノフォア抗生物質は、海産魚の魚体に寄生したCryptocaryon irritans虫体に対する殺虫効果及び成長抑制効果を有し、かつ海産魚の白点病による死亡を防止する作用を有する。従って、イオノフォア抗生物質を海産魚に投与すれば海産魚の白点病が予防治療できる。   As will be described later in Examples, the ionophore antibiotic has an insecticidal effect and a growth-inhibiting effect on Cryptocarriton irritans parasites of marine fish, and has an action of preventing death of marine fish due to white spot disease. Therefore, white spot disease of marine fish can be prevented and treated by administering ionophore antibiotics to marine fish.

イオノフォア抗生物質の投与手段は、特に限定されないが経口投与が簡便かつ安全であることから好ましい。イオノフォア抗生物質を経口投与するには、飼料(餌)中に混合して投与するのが好ましい。当該飼料又は飼料添加物中のイオノフォア抗生物質の濃度は、4質量百万分率以上、さらに4〜500質量百万分率、特に10〜500質量百万分率とするのが好ましい。また、イオノフォア抗生物質の海産魚の体重1kgあたりの投与量としては、1日あたり0.1〜50mg、さらに0.25〜25mgが好ましい。   The means for administering the ionophore antibiotic is not particularly limited, but oral administration is preferred because it is simple and safe. In order to orally administer the ionophore antibiotic, it is preferable to administer the ionophore antibiotic in a feed (food). The concentration of the ionophore antibiotic in the feed or feed additive is preferably 4 parts by weight or more, more preferably 4 to 500 parts by weight, and particularly preferably 10 to 500 parts by weight. The dose of ionophore antibiotic per 1 kg body weight of marine fish is preferably 0.1 to 50 mg, more preferably 0.25 to 25 mg per day.

また、本発明の白点病予防治療剤は、飼料中に混合せず別途投与してもよい。その場合の形態としては粉体、粒状物、ペレット等が挙げられる。   The white spot disease preventive / therapeutic agent of the present invention may be separately administered without being mixed in the feed. Examples of the form include powder, granule, pellet and the like.

前記の飼料、飼料添加物、その他の形態にする場合には、イオノフォア抗生物質以外に、例えば、炭酸カルシウム、りん酸カルシウム、硫酸カルシウム、小麦粉、デンプン、デキストリン、飼料用酵母や飼料用原料の穀類、そうこう類、粕類と混合して希釈したり、あるいはビタミン、ミネラル等のプレミックス又はこれらプレミックスを配合した魚類用餌料に添加して使用してもよい。また生餌の場合、アルギン酸ナトリウム、グアーガム等の添加剤を同時に使用してもよい。   In the case of the above-mentioned feed, feed additive, and other forms, in addition to ionophore antibiotics, for example, calcium carbonate, calcium phosphate, calcium sulfate, flour, starch, dextrin, feed yeast and feed raw material grains They may be mixed with algae and moss and diluted, or added to premixes of vitamins, minerals, etc. or fish feeds containing these premixes. In the case of raw food, additives such as sodium alginate and guar gum may be used at the same time.

本発明の白点病予防治療剤の対象海産魚としては、全ての海産真骨魚であれば限定されないが、例えばマダイ、イシダイ、イシガキダイ、スズキ、イサキ、マアジ、シマアジ、マサバ、クロマグロ、カンパチ、ブリ、ヒラマサ、マハタ、クエ、キジハタ、スギ等のスズキ目及びオニオコゼ、カサゴの属するカサゴ目、ヒラメ、マコガレイ、ホシガレイ、マツカワ等の属するカレイ目、トラフグの属するフグ目の海産魚が挙げられる。   The target marine fish of the white spot disease preventive and therapeutic agent of the present invention is not limited as long as it is all marine true bone fish. Examples include sea bass fish such as yellowtail, hiramasa, mahata, kue, pheasant grouper, cedar, etc.

本発明の白点病予防治療剤の投与時期は、Cryptocaryon irritansが寄生する前から投与することもでき、白点病の症状が発見された時点で投与することもできる。   The administration timing of the white spot disease preventive / therapeutic agent of the present invention can be administered before Cryptocalyon irritans parasitizes, or can be administered when a symptom of white spot disease is discovered.

次に実施例を挙げて本発明をさらに詳細に説明する。   EXAMPLES Next, an Example is given and this invention is demonstrated still in detail.

実施例1
(方法)
非特許文献4の記載に準じて、魚類培養細胞層の上に細胞培養用培地とアガロースゲルを重層した海産魚白点虫用培地のアガロースゲルの中にイオノフォア抗生物質を各種薬剤を様々な濃度で添加し、魚類細胞層とアガロースゲル層の間に海産魚白点虫のセロント懸濁液をマイクロピペットを用いて挿入し、挿入直後のセロントを数え、さらに、セロントが成長して得られるトロホントの数を毎日数えて生残率を求めた。
Example 1
(Method)
According to the description of Non-Patent Document 4, various concentrations of ionophore antibiotics in various concentrations of ionophore antibiotics in an agarose gel of a marine fish white spot insect medium in which a cell culture medium and an agarose gel are overlaid on a fish culture cell layer. Add the Seronto suspension of marine fish white spot worms between the fish cell layer and the agarose gel layer using a micropipette, count the Seronto immediately after insertion, and then add the Seronto The survival rate was calculated by counting the number of

(結果)
図1〜図4に、各種イオノフォア抗生物質を添加した培養内におけるCryptocaryon irritansのトロホントの生残率の変化を示す。図1〜図4から明らかなように、サリノマイシンナトリウム、モネンシンナトリウム、ナラシン及びセンデュラマイシンナトリウムのいずれもトロホントの生残率を顕著に抑制した。
(result)
FIGS. 1 to 4 show changes in the survival rate of Cryptocaryron irritans trofonds in cultures added with various ionophore antibiotics. As is clear from FIGS. 1 to 4, all of salinomycin sodium, monensin sodium, narasin, and senduramycin sodium significantly suppressed the survival rate of trohont.

実施例2
ヒラメ稚魚(全長約5cm)にサリノマイシンナトリウムならびにセンデュラマイシンナトリウムを添加した飼料(濃度200ppm)を飽食給餌し、セロント懸濁液の中に浸漬して攻撃して、ヒラメを離脱したプロトモントの数とプロトモントがシスト化して形成されたトモントの直径を計測した。
Example 2
Protomont's flounder (total length approximately 5cm) was fed with a diet (concentration of 200ppm) supplemented with salinomycin sodium and senduramycin sodium, immersed in the Seronto suspension, attacked, and protomonts withdrawn from flounder The diameter of the tomont formed by cystizing the number and the protomont was measured.

5日間薬剤を投与したのち、C.irritansのセロントで攻撃したヒラメから回収されたトロホント数と回収されたトロホントがシスト化して形成されたトモントの直径を表1に示す。   After administration of the drug for 5 days, C.I. Table 1 shows the number of trohonts recovered from Japanese flounder attacked by the irritans seronto and the diameter of the tomont formed by cysting the recovered trohont.

Figure 0005553337
Figure 0005553337

C.irritansによる攻撃前の5日間と攻撃後の3日間薬剤を投与したヒラメから回収されたトロホント数と回収されたトロホントがシスト化して形成されたトモントの直径を表2に示す。   C. Table 2 shows the number of trohonts recovered from Japanese flounder administered with the drug for 5 days before the irritans attack and 3 days after the attack, and the diameter of the tomont formed by cysting the recovered trohont.

Figure 0005553337
Figure 0005553337

表1及び表2の結果からサリノマイシンナトリウムでは、回収された虫体の数、トモントの直径ともに有意に小さくなった。センデュラマイシンナトリウムでは、有意差はなかったものの回収虫体数は少なくなり、得られたトモントの直径は有意に小さくなった。このことから、イオノフォア抗生物質は魚に寄与しているCryptocaryon irritans虫体に対して、殺虫効果と成長抑制効果を有することが確認された。   From the results of Tables 1 and 2, with salinomycin sodium, both the number of insects recovered and the diameter of Tomont were significantly reduced. In Senduramycin sodium, although there was no significant difference, the number of recovered worms decreased, and the diameter of the obtained tomont was significantly reduced. From this, it was confirmed that the ionophore antibiotic has an insecticidal effect and a growth inhibitory effect on the Cryptocaryon irritans parasite that contributes to fish.

実施例3
サリノマイシンナトリウム(200ppm)を添加した飼料を5日間飽食給餌したヒラメ稚魚をセロント懸濁液で攻撃し、その後もサリノマイシンナトリウムを毎日給餌し、死亡までの時間と観察した。
その結果、図5に示すように、サリノマイシンナトリウム投与区では明らかにヒラメの白点病による死亡までの時間が抑制された。
Example 3
Shrimp larvae fed with a diet supplemented with salinomycin sodium (200 ppm) for 5 days were challenged with a seronto suspension, and thereafter salinomycin sodium was fed daily and observed as time to death.
As a result, as shown in FIG. 5, in the salinomycin sodium administration group, the time until death due to white spot disease of flounder was clearly suppressed.

Claims (2)

サリノマイシン、モネンシン、ナラシン、センデュラマイシン及びこれらの塩から選ばれる1種又は2種以上のイオノフォア抗生物質を有効成分とする海産魚白点病予防治療剤。 A marine fish white spot disease preventive or therapeutic agent comprising one or more ionophore antibiotics selected from salinomycin, monensin, nalasin, senduramycin and salts thereof as an active ingredient. 投与形態が、経口投与である請求項記載の海産魚白点病予防治療剤。 Dosage form, marine fish white spot disease prevention treatment agent according to claim 1 is administered orally.
JP2010016279A 2010-01-28 2010-01-28 Marine fish white spot disease preventive and therapeutic agent Expired - Fee Related JP5553337B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010016279A JP5553337B2 (en) 2010-01-28 2010-01-28 Marine fish white spot disease preventive and therapeutic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010016279A JP5553337B2 (en) 2010-01-28 2010-01-28 Marine fish white spot disease preventive and therapeutic agent

Publications (2)

Publication Number Publication Date
JP2011153103A JP2011153103A (en) 2011-08-11
JP5553337B2 true JP5553337B2 (en) 2014-07-16

Family

ID=44539336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010016279A Expired - Fee Related JP5553337B2 (en) 2010-01-28 2010-01-28 Marine fish white spot disease preventive and therapeutic agent

Country Status (1)

Country Link
JP (1) JP5553337B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104255607A (en) * 2014-09-25 2015-01-07 广东省昆虫研究所 Method for simple and rapid removal of tilapia invading aquaculture pond
CN110384059A (en) * 2019-09-06 2019-10-29 西南大学 A kind of control method of fresh-water fishes ich
CN111700010A (en) * 2020-04-17 2020-09-25 浙江师范大学 Technical method for preventing and treating ichthyophthiriasis of cultured fishes by utilizing artificial flow generation and ozone
CN112690375B (en) * 2020-12-25 2022-10-11 广东海大集团股份有限公司 Premix for preventing and treating white spot disease of marine fish and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081034A (en) * 1999-07-09 2001-03-27 Fujisawa Pharmaceut Co Ltd Antiprotozoal agent for animal
JP2009108004A (en) * 2007-10-31 2009-05-21 Avss Co Ltd Beta-nodavirus infection inhibitor for fish

Also Published As

Publication number Publication date
JP2011153103A (en) 2011-08-11

Similar Documents

Publication Publication Date Title
Ogawa Diseases of cultured marine fishes caused by Platyhelminthes (Monogenea, Digenea, Cestoda)
US8100086B2 (en) Method of promoting the reproductive performance of penaeus shrimps
Yamamoto et al. Efficacy of oral praziquantel treatment against the skin fluke infection of cultured chub mackerel, Scomber japonicus
US11266168B2 (en) Probiotic bacteria for fish
CN110178973A (en) A kind of pharmaceutical chemistry additive for preventing and treating litopenaeus vannamei liver sausage born of the same parents worm
KR101817817B1 (en) Fish parasite extermination agent and extermination method
Wongtavatchai et al. Effect of AquaVacTM VibromaxTM on size and health of post larva stage of Pacific White shrimp Litopenaeus vannamei and Black Tiger shrimp Penaeus monodon
JP5553337B2 (en) Marine fish white spot disease preventive and therapeutic agent
Plumb Overview of warmwater fish diseases
Regunathan et al. Control of Vibrio spp. in shrimp hatcheries using the green algae Tetraselmis suecica
DK202070450A1 (en) Probiotic bacteria for fish
Simpson et al. Diseases associated with stranding and captivity
Parmar et al. Therapeutic potentiality of florfenicol against vibriosis in Litopenaeus vannamei
JP4225385B2 (en) Disinfectant for fish pathogenic bacteria and method for the disinfection
Loh et al. Fish vetting essentials
Yasin et al. Control of fish diseases using antibiotics and other antimicrobial agents
El-Deen et al. Field studies of caligus parasitic infections among cultured seabass (Dicentrarchus labrax) and mullet (Mugil cephalus) in marine fish farms with emphasis on treatment trials
US6705556B2 (en) Composition and method for inducing tolerance to viral infection in aquatic animals
Mallik et al. Determination of lethal dose of Aeromonas hydrophila RTMCX1 and in vitro efficacy of oxytetracycline hydrochloride in golden mahseer, Tor putitora (Hamilton, 1822)
CN110721174B (en) Medicine for preventing and treating fish myxosporidiosis
JP2001122717A (en) Antiparasitic and antimicrobial agent for fishes
JP2006077000A (en) Method for exterminating fish parasite and method for preventing infection
ISLAM Impact of quorum sensing on the virulence of Vibrio crassostreae and Vibrio tasmaniensis in vitro and in vivo in blue mussel larvae
Bowden et al. Management of finfish and shellfish larval health in aquaculture hatcheries
SISAL Differential expression of immune-related genes in Pacific white shrimp, Litopenaeus vannamei, previously reared in biofloc and challenged with Vibrio harveyi.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140218

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140521

R150 Certificate of patent or registration of utility model

Ref document number: 5553337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees